Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2015 02:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN® Filo and Janssen's AdVac® technology

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} First human trial of the MVA-BN® Filo/AdVac®...
January 06, 2015 02:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic offentliggør påbegyndelsen af klinisk fase 1 forsøg med MVA-BN® Filo og AdVac® prime-boost forsøgsvaccinen mod ebola

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Det første forsøg i mennesker med den...
December 10, 2014 01:40 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC(R) in Prostate Cancer

KVISTGAARD, Denmark, Dec. 10, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3...
December 10, 2014 01:30 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC® in Prostate Cancer

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} KVISTGAARD, Denmark, December 10, 2014 - Bavarian...
December 10, 2014 01:30 ET | Source: Bavarian Nordic A/S

Bavarian Nordic opnår mål for rekruttering af patienter i det pivotale fase 3 forsøg med PROSTVAC® til behandling af prostatacancer

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} KVISTGÅRD, Danmark - 10. december 2014 - Bavarian...
December 04, 2014 01:38 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Announces First Subject Dosed with MVA-BN(r) Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines

First human trial investigating MVA-BN® Filo as an Ebola vaccine MVA-BN Filo is being investigated as a booster in an ongoing Phase study 1 of the cAd3-EBO Z vaccine being developed by...
December 04, 2014 01:30 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Announces First Subject Dosed with MVA-BN® Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} First human trial investigating MVA-BN® Filo...
December 04, 2014 01:30 ET | Source: Bavarian Nordic A/S

Bavarian Nordic offentliggør at første forsøgsperson er vaccineret med MVA-BN® Filo i et nyt fase 1 forsøg med en prime-boost forsøgsvaccine mod ebola

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Forsøget er det første i mennesker, hvor...
November 30, 2014 06:00 ET | Source: Bavarian Nordic A/S

Total number of voting rights and share capital in Bavarian Nordic A/S

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} KVISTGAARD, Denmark, November 30, 2014 - Bavarian...
November 30, 2014 06:00 ET | Source: Bavarian Nordic A/S

Indberetning af aktiekapital og stemmerettigheder for Bavarian Nordic A/S

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} KVISTGÅRD, Danmark - 30. november 2014 - Bavarian...